Cyclosporine in the treatment of dermatologie disease: An update

Mayo Clinic Proceedings

Volumn 71, Issue 12, 1996, Pages 1182-1191

  Lim, Katherine K ^a   Daniel, W P ^a,b   Schroeter, Arnold L ^c   Sabers, Candace J ^b,c   Abraham, Robert T ^b,c   Pittelkow, Mark R ^b,c  

^a Department of Dermatology ^*  (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANDROGEN; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CIMETIDINE; CONTRACEPTIVE AGENT; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; CYCLOSPORIN A; DANAZOL; DEXAMETHASONE; DIGOXIN; DIURETIC AGENT; ERYTHROMYCIN; KETOCONAZOLE; MELPHALAN; MEVINOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; PHENOBARBITAL; PHENYLBUTAZONE; PHENYTOIN; RAPAMYCIN; RIFAMPICIN; SULFINPYRAZONE; TACROLIMUS;

ATOPIC DERMATITIS; BEHCET DISEASE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; EPIDERMOLYSIS BULLOSA ACQUISITA; HUMAN; LICHEN PLANUS; NEPHROTOXICITY; PRACTICE GUIDELINE; PSORIASIS; PYODERMA GANGRENOSUM; REVIEW; SKIN DISEASE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0030317639     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/71.12.1182     Document Type: Review

References (92)

1. Kahan BD. Cyclosporine. N Engl J Med 1989; 321:1725-1738
2. Holt DW, Mueller EA, Kovarik JM, van Bree JB, Richard F, Kutz K. Sandimmun Neoral pharmacokinetics: impact of the new oral formulation. Transplant Proc 1995; 27:1434-1437
3. Watkins PB. The role of cytochromes P-450 in cyclosporine metabolism. J Am Acad Dermatol 1990; 23:1301-1309
4. Mockli G, Kabra PM, Kurtz TW. Laboratory monitoring of cyclosporine levels: guidelines for the dermatologist. J Am Acad Dermatol 1990; 23:1275-1278
5. Woo J. Therapeutic monitoring of cyclosporine. Ann Clin Lab Sei 1994; 24:60-68
6. Elliot JF, Lin Y, Mizel SB, Bleackley RC, Harnish DG, Paetkau V. Induction of interleukin 2 messenger RNA inhibited by cyclosporin A. Science 1984; 226:1439-144 f
7. Heitman J, Movva NR. Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991:253:905-909
8. Bierer BE. Manila PS, Standaert RF, Herzenberg LA, Burakoff SJ, Crabtree G, et al. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sei USA 1990:87:9231-9235
9. Bierer BE, Somers PK, Wandless TJ, Burakoff SJ, Schreiber SL. Probing immunosuppressant action with a nonnatural immunophilin ligand. Science 1990:250:556-559
10. Bram RJ, Hung DT. Martin PK, Schreiber SL, Crabtree GR. Identification of the immunophiiins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. Mol Cell Biol 1993; 13:4760-4769
11. Liu J, Fanner JD Jr, Lane WS, Frieman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66:807-815
12. Wong RL, Winslow CM, Cooper KD. The mechanisms of action of cyclosporin A in the treatment of psoriasis. Immunol Today 1993; 14:69-74
13. Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH, et al. Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial. N Engl J Med 1991; 324:277-284
14. Laburte C, Grossman R, Abi-Rached J, Abeywickrama KH, Dubertret L. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. BrJDermatol 1994; 130:366-375
15. Griffiths CE, Powles AV, Leonard JN, Fry L, Baker BS, Valdimarsson H. Clearance of psoriasis with low dose cyclosporin. BMJ 1986; 293:731-732
16. Fradin MS, Ellis CN, Voorhees JJ. Efficacy of cyclosporin A in psoriasis: a summary of the United States' experience. Br J Dermatol 1990; 122(Suppl 36):21-25
17. Mrowietz U, Farber L, Henneickevonzepelin HH, Bachmann H, Welzel D, Christophers E, et al. Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: results of a multicenter study. J Am Acad Dermatol 1995; 33:470-475
18. Peluso AM, Bardazzi F, Tosti A, Varotti C. Intermittent cyclosporin A treatment of severe plaque psoriasis: long-term follow-up of 26 patients. Acta Derm Venereol Suppl (Stockh) 1994; 186:90-91
19. Garcovich A, Gatti M, Pompili A, Olivetti G, Catamo F. Short-term treatment with cyclosporin in severe psoriasis: four years of experience. Acta Derm Venereol Suppl (Stockh) 1994; 186:92-93
20. Amerio P, Gravante M, Andreassi M, Masci S. Cyclical immunotherapy in patients with psoriasis. Acta Derm Venereol Suppl (Stockh) 1994; 186:101-102
21. Studio Italiano Multicentrico nella Psoriasi (SIMPSO). Management of erythrodermic psoriasis with low-dose cyclosporin. Dermatology 1993; 187(Suppl):30-37
22. Fradin MS, Ellis CN, Voorhees JJ. Rapid response of von Zumbusch psoriasis to cyclosporine. J Am Acad Dermatol 1990:23:925-926
23. Peter RU, Ruzicka T, Donhauser G, Braun-Falco O. Acrodermatitis continua-type of pustular psoriasis responds to low-dose cyclosporine. J Am Acad Dermatol 1990; 23:515-516
24. Gupta AK, Maltesen EL, Ellis CN, Ho VC, Tellner DC, Voorhees JJ, et al. Cyclosporine in the treatment of psoriatic arthritis. Arch Dermatol 1989; 125:507-510
25. Arnold WP, Gerritsen MJ, van de Kerkhof PC. Response of nail psoriasis to cyclosporin [letter]. BrJDermatol 1993; 129:750-751
26. Ho VC, Griffiths CE, Ellis CN, Gupta AK, McCuaig CC, Nickoloff BJ, et al. Intralesional cyclosporine in the treatment of psoriasis: a clinical, immunologie, and pharmacokinetic study. J Am Acad Dermatol 1990; 22:94-100
27. Griffiths CE, Powles AV, Baker BS, Fry L, Valdimarsson H. Topical cyclosporin and psoriasis [letter]. Lancet 1987; 1:806
28. Kauvar AB, Stiller MJ. Cyclosporine in dermatology: pharmacology and clinical use. Int J Dermatol 1994; 33:86-96
29. Brechtel B, Wellenreuther U, Toppe E, Czarnetzki BM. Combination of etretinate with cyclosporine in the treatment of severe recalcitrant psoriasis. J Am Acad Dermatol 1994; 30:1023-1024
30. Grossman RM, Thivolet J, Claudy A, Souteyrand P, Guilhou JJ, Thomas P, et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol 1994; 31:68-74
31. Mahrle G, Schulze HJ, Farber L, Weidinger G, Steigleder GK. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995; 32:78-88
32. Bourke JF, Berth-Jones J, Holder J, Graham-Brown RAC. A new microemulsion formulation of cyclosporin (Neoral) is effective in the treatment of cyclosporin-resistant dermatoses. Br J Dennatol 1996; 134:777-779
33. Ho VC, Gupta AK, Eilis CN, Nickoioff BJ, Voorhees JJ. Treatment of severe lichen planus with cyclosporine. J Am Acad Dermatol 1990; 22:64-68
34. Higgins EM, Munro CS, Friedmann PS, Marks JM. Cyclosporin A in the treatment of lichen planus [letter]. Arch Dermatol 1989; 125:1436
35. Grattan CEH, Boon AP, Gregory J. A preliminary open study of topical cyclosporin for hypertrophie lichen planus. J Dermatol Treat 1989; 1:39-41
36. Eisen D, Ellis CN, Duell EA, Griffiths CE, Voorhees JJ. Effect of topical cyclosporine rinse on oral lichen planus: a double-blind analysis. N Engl J Med 1990; 323:290-294
37. Lopez Lopez J, Rosello Llabres X. Cyclosporine A, an alternative to the oral lichen planus erosive treatment. Bull Group Int Rech Sei Stomatol Odontol 1995; 38:33-38
38. Voute AB, Schulten EA, Langendijk PN, Nieboer C, van der Waal I. Cyclosporin A in an adhesive base for treatment of recalcitrant oral lichen planus: an open trial. Oral Surg Oral Med Oral Pathol 1994; 78:437-441
39. Suss R, al-Ayoubi M, Ruzicka T. Cyclosporine therapy in Behçet's disease. J Am Acad Dermatol 1993; 29:101-102
40. Pacor ML, Biasi D, Lunardi C, Cortina P, Caramaschi P, Girelli D, et al. Cyclosporin in Behçet's disease: results in 16 patients after 24 months of therapy. Clin Rheumatol 1994; 13:224-227
41. Taylor RS III, Cooper KD, Headington JT, Ho VC, Ellis CN, Voorhees JJ. Cyclosporine therapy for severe atopic dermatitis. J Am Acad Dermatol 1989; 21:580-583
42. Sowden JM, Berth-Jones J, Ross JS, Motley RJ, Marks R, Finlay AY, et al. Double-blind, controlled, crossover study of cyclosporine in adults with severe refractory atopic dermatitis. Lancet 1991; 338:137-140
43. van Joost T, Heule F, Korstanje M, van den Broek MJ, Stenveld HJ, van Vloten WA. Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study. BrJ Dermatol 1994; 130:634-640
44. Munro CS, Higgins EM, Marks JM, Daly BM, Friedmann PS, Shuster S. Cyclosporin A in atopic dermatitis: therapeutic response is dissociated from effects on allergic reactions. Br J Dermatol 1991 ; 124:43-48
45. Munro CS, Levell NJ, Shuster S, Friedmann PS. Maintenance treatment with cyclosporin in atopic eczema. Br J Dermatol 1994; 130:376-380
46. de Prost Y, Bodemer C, Teillac D. Randomised double-blind placebo-controlled trial of local cyclosporin in atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1989; 144:136-138
47. Matis WL, Ellis CN, Griffiths CE, Lazarus GS. Treatment of pyoderma gangrenosum with cyclosporine. Arch Dermatol 1992; 128:1060-1064
48. Mrowietz U, Christophers E. Clearing of pyoderma gangrenosum by intralesional cyclosporin A [letter]. Br J Dermatol 1991; 125: 499
49. Gupta AK, Ellis CN, Nickoioff BJ, Goldfarb MT, Ho VC, Rocher LL, et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses: a clinical and immunopathologic analysis. Arch Dermatol 1990; 126:339-350
50. Merle C, Blanc D, Zultak M, van Landuyt H, Drobacheff C, Laurent R. Intractable epidermolysis bullosa acquisita: efficacy of ciclosporin A. Dermatologica 1990; 181:44-47
51. Gupta AK, Ellis CN, Cooper KD, Nickoioff BJ, Ho VC, Chan LS, et al. Oral cyclosporine for the treatment of alopecia areata: a clinical and immunohistochemical analysis. J Am Acad Dermatol 1990; 22:242-250
52. Rongioletti F, Guarrera M, Tosti A, Guerra L, Pigatto P. Topical cyclosporin A fails to improve alopecia areata: a double blind study. J Dermatol Treat 1992; 3:13-14
53. Frances C, Branche! MC, Blétry O, Lefevre C, Boisnic S, Kern P, et al. Skin collagen from scleroderma patients before and after cyclosporin A treatment. Clin Exp Dermatol 1988; 13:1-3
54. Groisser DS, Griffiths CE, Ellis CN, Voorhees JJ. A review and update of the clinical uses of cyclosporine in dermatology. Dermatol Clin 1991; 9:805-817
55. Casoli P, Carretti C, Tumiati B. Scleroderma renal crisis as a possible complication of cyclosporin A withdrawal. Clin Rheumatol 1994; 13:126-128
56. Duschet P, Schwarz T, Oppolzer G, Gschnait F. Persistent light reaction: successful treatment with cyclosporin A. Acta Derm Venereol 1988; 68:176-178
57. Gardeazabal J. Arregui MA. Gil N, Landa N, Raton JA, Diaz-Perez JL. Successful treatment of musk ketone-induced chronic actinic dermatitis with cyclosporine and PUVA. J Am Acad Dermatol 1992; 27:838-842
58. Morris PG, Camp RD, Hawk JL. Actinic reticuloid: response to cyclosporine. J Am Acad Dermatol 1989; 21:307-309
59. Thestrup-Pedersen K, Zachariae C, Kaltoft K, Pallesen G, Sogaard H. Development of cutaneous pseudolymphoma following ciclosporin therapy of actinic reticuloid. Dermatologica 1988; 177:376-381
60. Cunliffe WJ. Pemphigus foliaceus and response to cyclosporin. Br J Dermatol 1987; 117(Suppl 32): 114-116
61. Campolmi P, Bonan P, Lotti T, Palleschi GM, Fabbri P, Panconesi E. The role of cyclosporine A in the treatment of pemphigus erythematosus. Int J Dermatol 1991; 30:890-892
62. Barthélémy H, Frappaz A, Cambazard F, Mauduit G, Rouchouse B, Kanitakis J, et al. Treatment of nine cases of pemphigus vulgaris with cyclosporine. J Am Acad Dermatol 1988; 18:1262-1266
63. Bianchi L, Gatti S, Nini G. Bullous pemphigoid and severe erythrodermic psoriasis: combined low-dose treatment with cyclosporine and systemic steroids [letter]. J Am Acad Dermatol 1992; 27:278
64. Azana JM, de Misa RF, Boixeda JP, Ledo A. Topical cyclosporine for cicatricial pemphigoid [letter]. J Am Acad Dermatol 1993; 28:134-135
65. Wilkel CS, McDonald CJ. Cyclosporine therapy for bullous erythema multiforme [letter]. Arch Dermatol 1990; 126:397-398
66. Berth-Jones J, Smith SG, Graham-Brown RAC. Benign familial chronic pemphigus (Hailey-Hailey disease) responds to cyclosporin. Clin Exp Dermatol 1995; 20:70-72
67. Lapidoth M, David M, Ben-Amitai D, Katzenelson V, Lustig S, Sandbank M. The efficacy of combined treatment with prednisone and cyclosporine in patients with pemphigus: preliminary study. J Am Acad Dermatol 1994; 30:752-757
68. Jitsukawa K, Ring J, Weyer U, Kimmig W, Radioff H. Topical cyclosporine in chronic benign familial pemphigus (Hailey-Hailey disease). J Am Acad Dermatol 1992; 27:625-626
69. Fox DA. McCune WJ. Immunosuppressive drug therapy of systemic lupus erythematosus. Rheum Dis Clin North Am 1994 Feb; 20:265-299
70. Mehregan DR. Su WP. Cyclosporine treatment for dermatomyositis/ polymyositis. Cutis 1993; 51:59-61
71. Heckmatt J, Hasson N, Saunders C. Thompson N, Peters AM, Cambridge G. et al. Cyclosporin in juvenile dermatomyositis. Lancet 1989; 1:1063-1066
72. Hamill G, Saunders C, Heckmatt J, Dubowitz V, Stanhope R. "Catch-up" growth in steroid dependent dermatomyositis treated with cyclosporin-A. EurJMed 1992; 1:16-18
73. Faulds D, Goa KL, Benfield P. Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993; 45:953-1040
74. Ho VC, Lui H, McLean DI. Cyclosporine in nonpsoriatic dermatoses. J Am Acad Dermatol 1990; 23:1248-1257
75. Filotico R, Vena GA, Coviello C, Angelini G. Cyclosporine in the treatment of generalized granuloma annulare. J Am Acad Dermatol 1994; 30:487-488
76. Reitamo S. Granlund H. Cyclosporin A in the treatment of chronic dermatitis of the hands. BrJ Dermatol 1994; 130:75-78
77. Fradin MS, Ellis CM, Voorhees JJ. Management of patients and side effects during Cyclosporine therapy for cutaneous disorders. J Am Acad Dermatol 1990; 23:1265-1273
78. Penn I. Cancers following Cyclosporine therapy. Transplantation 1987; 43:32-35
79. Rodicio JL, Morales JM, Ruilope LM. Lipophilic dihydropyridines provide renal protection from cyclosporin toxicity. J Hypertens 1993; ll(Suppl6):S21-S25
80. Feutren G, Abeywickrama K, Friend D, von Graffenried B. Renal function and blood pressure in psoriatic patients treated with cyclosporin A. BrJ Dermatol 1990; 122(Suppl 36):57-69
81. Korstanje MJ, Bilo HJ, Stoof TJ. Sustained renal function loss in psoriasis patients after withdrawal of low-dose cyclosporin therapy. BrJ Dermatol 1992; 127:501-504
82. Zachariae H, Hansen HE, Kragballe K, Olsen S. Morphologic renal changes during Cyclosporine treatment of psoriasis: studies on pretreatment and posttreatment kidney biopsy specimens. J Am Acad Dermatol 1992:26:415-419
83. Svenson KL, Hallgren R. Long-term follow-up of cyclosporin A treated patients with Behçet disease. In: O'Duffy JD, Kokmen E. editors. Behçet Disease: Basic and Clinical Aspects. New York: Marcel Dekker, 1991: 613-617
84. Messana JM, Johnson KJ, Mihatsch MJ. Renal structure and function effects after low dose Cyclosporine in psoriasis patients: a preliminary report. Clin Nephrol 1995; 43:150-153
85. Textor SC. Canzanello VJ, Taler SJ, Wilson DJ, SchwärtJ. LL, Augustine JE, et al. Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc 1994; 69:1182-1193
86. CurtisJJ. Management of hypertension after transplantation. Kidney IntSuppl 1993;43:S45-S49
87. Roullet JB. Xue H, McCarron DA, Holcomb S, Bennett WM. Vascular mechanisms of cyclosporin-induced hypertension in the rat. J Clin Invest 1994; 93:2244-2250
88. Korstanje MJ. How to improve the risk-benefit ratio of cyclosporin therapy for psoriasis. Clin Exp Dermatol 1992; 17:16-19
89. First MR, Schroeder TJ, Michael A, Hariharan S. Weiskittel P, Alexander JW. Cyclosporine-ketoconazole interaction: long-term follow-up and preliminary results of a randomized trial. Transplantation 1993:55:1000-1004
90. Olshan AF, Mattison DR, Zwanenburg TS. Cyclosporine A: review of genotoxicity and potential for adverse human reproductive and developmental effects; report of a working group on the genotoxicity of Cyclosporine A, August 18. 1993. Mutât Res 1994; 317:163173
91. Powles AV, Cook T, Hulme B, Baker BS, Lewis HM, Thomas E. et al. Renal function and biopsy findings after 5 years' treatment with low-dose cyclosporin for psoriasis. Br J Dermatol 1993; 128:159-165
92. Gilbert SC, Emmett M, Menter A, Silverman A, Kliritmalm G. Cyclosporine therapy for psoriasis: serum creatinine measurements are an unreliable predictor of decreased renal function. J Am Acad Dermatol 1989:21:470-474